Orexo to Present at Jefferies 2016 Healthcare Conference, NYC

UPPSALA, Sweden--()--Regulatory News:

Orexo AB (publ) (STO:ORX) hereby announces that Henrik Juuel, EVP and Chief Financial Officer, Orexo AB, and Robert A. DeLuca, President of Orexo US, Inc., will present the company and hold a Q&A session at the 2016 Jefferies Healthcare Conference hosted by Jefferies in New York City, on Wednesday, June 8, 2016 at 2:00 pm local time.

For information about the conference, please visit http://www.jefferies.com/OurFirm/Conferences/325/270

The presentation will be made available at www.orexo.com following the conference

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarter and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit www.orexo.com. To read more about Zubsolv and opioid dependence, please visit www.zubsolv.com and www.outthemonster.com.

This information was brought to you by Cision http://news.cision.com

Contacts

Orexo
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00
E-mail: ir@orexo.com
or
Lena Wange, IR & Communications Manager
Tel: +46 (0)18-780 88 00
E-mail: ir@orexo.com

Contacts

Orexo
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00
E-mail: ir@orexo.com
or
Lena Wange, IR & Communications Manager
Tel: +46 (0)18-780 88 00
E-mail: ir@orexo.com